SENOCAD

The prediction of the response to NACT is a challenging clinical problem. We have designed a unique AI-powered method for the early prediction of the response to NACT. The proof of concept of our prediction method has given promising results in the case of locally advanced breast cancer. Now, these results must be validated by a large-scale multicentric clinical validation. Later on, our prediction method will be applied in cancer of other organs.

Also known as: SenoCAD Research, SenoCAD Research GmbH

Registration numbers: HRB 710936 (W)

VAT numbers: DE275260773

Primary location: Karlsruhe Germany